Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 7/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4776817 | 0.99 | HTR1A (0.56) | HTR1AADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL4725722 | 0.99 | HTR1A (0.56) | HTR1AADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL5768086 | 0.85 | HTR1A (0.58) | HTR1A | |
| SCHEMBL4861936 | 0.84 | DRD2 (0.54) | HTR1AALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL8055394 | 0.75 | HTR1A (0.71) | HTR1AADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL4781671 | 0.73 | HTR1A (0.98) | HTR1A | |
| SCHEMBL4797140 | 0.72 | HTR1A (0.93) | HTR1A | |
| SCHEMBL4903356 | 0.72 | HTR1A (0.91) | HTR1A | |
| SCHEMBL345500 | 0.71 | HTR1A (0.65) | HTR1AADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL7846002 | 0.70 | ALDH1A1 (0.44) | ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200470-A1 | Diaza- or Thiazadione Derivatives With Neuroprotective Activity | SCHWARTZ PHARMA S.L | 2008-08-21 | — | — | US | claimed |
| WO-2008015538-A2 | USE OF DIAZA- AND THIAZA-CYCLOALKANEDIONES FOR PREVENTING AND/OR TREATING PAIN AND /OR MIGRAINE | SCHWARZ PHARMA S.L. (ES) | 2008-02-07 | — | — | WO | claimed |
| EP-1711500-A1 | DIAZA- OR THIAZADIONE DERIVATIVES WITH NEUROPROTECTIVE ACTIVITY | Schwarz Pharma, s.l. (ES) | 2006-10-18 | — | — | EP | claimed |
| WO-2005075480-A1 | DIAZA- OR THIAZADIONE DERIVATIVES WITH NEUROPROTECTIVE ACTIVITY | SCHWARZ PHARMA S.L. (ES) | 2005-08-18 | — | — | WO | claimed |
| US-20080200470-A1 | Diaza- or Thiazadione Derivatives With Neuroprotective Activity | SCHWARTZ PHARMA S.L | 2008-08-21 | — | — | US | disclosed |
| US-20080200470-A1 | Diaza- or Thiazadione Derivatives With Neuroprotective Activity | SCHWARTZ PHARMA S.L | 2008-08-21 | — | — | US | disclosed |
| US-20080200470-A1 | Diaza- or Thiazadione Derivatives With Neuroprotective Activity | SCHWARTZ PHARMA S.L | 2008-08-21 | — | — | US | disclosed |
| WO-2008015538-A2 | USE OF DIAZA- AND THIAZA-CYCLOALKANEDIONES FOR PREVENTING AND/OR TREATING PAIN AND /OR MIGRAINE | SCHWARZ PHARMA S.L. (ES) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008015538-A2 | USE OF DIAZA- AND THIAZA-CYCLOALKANEDIONES FOR PREVENTING AND/OR TREATING PAIN AND /OR MIGRAINE | SCHWARZ PHARMA S.L. (ES) | 2008-02-07 | — | — | WO | disclosed |
| CN-1914209-A | Diaza- or thiazadione derivatives with neuroprotective activity | CEPA SCHWARZ PHARMA S L (ES) | 2007-02-14 | — | — | CN | disclosed |
| EP-1711500-A1 | DIAZA- OR THIAZADIONE DERIVATIVES WITH NEUROPROTECTIVE ACTIVITY | Schwarz Pharma, s.l. (ES) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005075480-A1 | DIAZA- OR THIAZADIONE DERIVATIVES WITH NEUROPROTECTIVE ACTIVITY | SCHWARZ PHARMA S.L. (ES) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200470-A1 | Diaza- or Thiazadione Derivatives With Neuroprotective Activity | HTR1A, HTR3A, HTR2A | HTR1A 1/4885ADRA1D 37/4885ADRA1A 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.